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Background: Indacaterol is a once-daily, long-acting b2-agonist bronchodilator that improves
dyspnoea and health status in patients with moderate-to-severe COPD. While its bronchodi-
lator effects have been shown to be maintained in different patient subgroups, effects on clin-
ical outcomes in certain subgroups are not yet defined.
Methods: Post-hoc analysis of pooled clinical study data to investigate efficacy and safety of
indacaterol compared with placebo and other long-acting bronchodilators (formoterol, salme-
terol, open-label tiotropium) in patient subgroups defined by COPD severity (GOLD stage II or
III; nZ 4082) and ICS use at baseline (no/yes; nZ 4088). Efficacy outcomes were trough (24-h
post-dose) FEV1, dyspnoea (transition dyspnoea index; TDI) and health status (St George’s
Respiratory Questionnaire; SGRQ) after 26 weeks.
Results: All active treatments significantly improved trough FEV1 and dyspnoea compared with
placebo, and all apart from open-label tiotropium improved health status compared with
placebo. Among active treatments, indacaterol 150 mg had the best overall efficacy profile
in the GOLD II and no-ICS subgroups. In the GOLD III and ICS subgroups, indacaterol 300 mg
had the best overall efficacy, including a marked effect on dyspnoea (1.4-point improvement
in TDI total score vs. placebo; p < 0.001). Within subgroups, the incidence of adverse events
was similar between treatments.346807; fax: þ32 16 346803.
zleuven.be (M. Decramer).
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224 M. Decramer et al.Conclusion: Indacaterolmaintained its efficacy regardless of disease severity or use of concurrent
ICS. Indacaterol 150 mg had the best overall efficacy profile in the GOLD stage II patients while, in
patients withmore severe disease, indacaterol 300 mg provided useful improvements in dyspnoea.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
Inhaled long-acting bronchodilators feature prominently
among the recommended pharmacological treatments for
the management of patients with chronic obstructive
pulmonary disease (COPD).1 Available long-acting bron-
chodilators include the twice-daily long-acting b2-agonists
(LABAs) formoterol and salmeterol, the once-daily long-
acting antimuscarinic (LAMA) tiotropium and, more
recently, the once-daily LABA indacaterol.
In placebo-controlled clinical studies, indacaterol has
demonstrated beneficial effects on lung function, symptoms
and health status in patients with moderate-to-severe
COPD.2e5 Most of the clinical trials with indacaterol have
included broadly similar proportions of patients with
moderate and severe COPD and similar proportions of
patients receiving concomitant inhaled corticosteroids (ICS)
or not at baseline. Many of the pivotal placebo-controlled
studies with indacaterol included pre-specified analyses of
the primary efficacy outcome (trough FEV1 after 12 weeks of
treatment) in patient subgroups defined according to factors
such as COPD severity, use of ICS, age and smoking status.
Adverse event data were also summarised for the subgroups.
The results showed that indacaterol maintained a significant
bronchodilator effect3,4 and a similar level of adverse events
in these subgroups. We report here on the results of a post-
hoc analysis conducted with the aim of exploring further the
effects of indacaterol in patient subgroups defined accord-
ing to COPD severity and ICS use at baseline, evaluating both
bronchodilator effects and clinical outcomes (dyspnoea and
health status) over a treatment period of 6 months. The
analysis was performed using data from more than 4000
patients pooled from three pivotal clinical studies that
included comparisons with the other available long-acting
inhaled bronchodilators: tiotropium, salmeterol and for-
moterol, all of which have been published individually.3e5Methods
Patients
The studies enrolled men and women aged 40 years with
a diagnosis of moderate-to-severe COPD (post-bronchodi-
lator FEV1 <80% and 30% predicted and FEV1/FVC <70%;
GOLD 2005 criteria), with a smoking history of 20 pack-
years. Patients with a recent respiratory tract infection or
COPD exacerbation were not included. Concomitant ICS use
was allowed but the dose and regimen had to remain stable
for the duration of each study. Patients who were receiving
LABA/ICS fixed-dose combinations prior to the study were
switched to equivalent ICS monotherapy. Patients were
allowed to use short-acting b2-agonists for symptom relief
as needed during the studies.Study design
Data were pooled from three randomised, double-blind,
placebo-controlled studies. Full details of the individual
studies have been published previously.3e5 The first was a 6
month study (NCT00567996) comparing indacaterol 150 mg
once daily with placebo and salmeterol 50 mg twice daily,
all given double-blind.5 The second was a 1 year study
(NCT00393458) comparing indacaterol 300 mg once daily
with placebo and formoterol 12 mg twice daily, all given
double-blind (6 month data were included in the present
analysis).3 The third was a 6 month study (NCT00463567)
comparing indacaterol 150 mg and 300 mg with placebo
(double-blind) and open-label tiotropium 18 mg, once
daily.4 The primary efficacy variable in each of those
studies was forced expiratory volume in 1 s (FEV1) at
‘trough’ (24 h following the previous morning dose of
indacaterol or tiotropium and 12 h following the previous
evening dose of formoterol or salmeterol) after 12 weeks’
treatment.
Assessments and variables
In the present analysis, efficacy was assessed after 26
weeks’ treatment. Using standardised spirometry,6 the
bronchodilator effect was measured as trough FEV1. Dysp-
noea was measured as transition dyspnoea index (TDI) total
score and the percentage of patients responding with
a minimum clinically important difference (MCID;
improvement of 1 point) in TDI total score, with associ-
ated odds ratios.7e9 Health status was measured using St
George’s Respiratory Questionnaire (SGRQ) total score and
the percentage of patients responding with the MCID of 4
units in SGRQ total score, with associated odds ratios.10,11
Adverse events were recorded and summarised.
Statistical analysis
Patients were divided into subgroups of GOLD stages II and
III, irrespective of ICS use, and into subgroups according to
ICS use, irrespective of GOLD stages. In each subgroup
(GOLD stages and ICS use) we performed separate statis-
tical analyses.
Trough FEV1 after 26 weeks of treatment was analysed
using a mixed-model analysis of covariance with treat-
ment as a fixed effect and baseline FEV1 and baseline
FEV1 reversibility (to salbutamol and to ipratropium) as
covariates. The same model (with appropriate covariates)
was used to analyse the TDI and SGRQ efficacy variables.
Missing TDI and SGRQ data were imputed with the last
observation (provided this was within the last 11 weeks)
carried forward. No powering or sample size calculations
were performed for this post-hoc analysis, although all
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variable described above. Additionally, one of the
studies5 was powered on SGRQ after 12 weeks of treat-
ment. No adjustment was made for multiplicity in the
present analyses. Differences between treatment groups
are presented as least squares mean values with associ-
ated 95% CI.Results
Patients
Data were available for 4082 patients with information on
GOLD severity stage and 4088 patients with information on
baseline ICS use. The difference is due to missing
screening data on lung function and therefore on COPD
severity. In the population defined by ICS use, 56% of
patients had no ICS use at baseline (‘no-ICS’) and 44% of
patients had baseline ICS use (‘ICS’). Among the latter ICS
patients, 52% had GOLD stage II disease. In the population
defined by GOLD stage, 58% of patients had COPD at
stages II and 42% had COPD at stages III. These two groups
contained a small proportion of patients with COPD at
GOLD stage I (3.9% of the total population) and stage IV
(1.0% of the total population). The reasons for this were
a protocol change early in one of the studies to use post-
bronchodilator (rather than pre-bronchodilator) spirom-
etry when screening for inclusion criteria, and that some
patients had borderline spirometry measurements that
shifted from GOLD II to I and from GOLD III to IV when
values were centrally re-calculated and adjusted for
ethnicity in the pooling exercise. These patients were
retained in the analysis and the two groups are referred to
here as GOLD III and GOLD IV. Overall, 40% of patients
with GOLD II stage disease and 50% of patients with GOLD
III stage disease were receiving ICS (Table 1). Baseline
data are shown in Table 2.
Patients with GOLD III stage disease were charac-
terised by lower (worse) dyspnoea scores, higher (worse)
health status scores and, in general, a larger proportion
of patients with exacerbations in the preceding 12
months compared with patients with GOLD II stage
disease (Table 2).
ICS patients were characterised by a longer duration of
COPD, a larger proportion of ex-smokers and, in general,
a larger proportion of patients with exacerbations withinTable 1 Summary of relationship between GOLD stage
and ICS use (all treatments).
ICS no ICS yes Total
GOLD II 1414 (35%a)
(60%b)
939 (23%a)
(40%b)
2353
GOLD III 861 (21%a)
(50%b)
868 (21%a)
(50%b)
1729
Total 2275 1807 4082
a Out of total (4082).
b ICS users out of GOLD severity.the previous 12 months compared with no-ICS patients
(Table 2).
There were no major imbalances at baseline between
treatment groups.
Six-month completion rates are shown in Table 3.
Completion rates were lower with placebo than with active
treatments in all subgroups, and activeeplacebo differ-
ences were generally more marked in the subgroups with
more severe disease and those on ICS.
Patients with GOLD II stage disease severity
Results for trough FEV1, TDI total score and SGRQ total
score are summarised in Fig. 1. The two indacaterol doses
were not significantly different from each other and were,
variously, significantly more effective than formoterol,
salmeterol and open-label tiotropium (trough FEV1), for-
moterol (TDI) and open-label tiotropium (SGRQ). The twice-
daily LABAs and open-label tiotropium were not signifi-
cantly different from each other. The effects of indacaterol
were above the MCID for all outcomes apart from the effect
of the 300 mg dose on SGRQ (at 3.9, just outside the 4.0
unit threshold). The patterns of treatment effects on TDI
and SGRQ scores were similar to the rates of responding
(MCID) patients for these outcomes (Table 4), although in
this subgroup the odds ratio for achieving the MCID was
significantly greater by 53% with indacaterol 300 mg than
with open-label tiotropium. The odds ratio for the SGRQ
MCID response was 47% greater with indacaterol 150 mg than
with open-label tiotropium (1.47 [95% CI 1.00, 2.16],
p Z 0.05). Raw mean changes from baseline in SGRQ total
score were 3.1 in placebo-treated patients, 5.2 with
open-label tiotropium, 5.8 with formoterol and salme-
terol, and 7.1 and 7.0 with indacaterol 150 mg and
300 mg treatments, respectively.
Patients with GOLD III stage disease severity
In this subgroup (Fig. 1), both indacaterol doses per-
formed better than the twice-daily LABAs in terms of
trough FEV1, and the 300 mg dose was better than inda-
caterol 150 mg and open-label tiotropium in its effect on
TDI. There was no significant difference between any
active treatments for SGRQ, although only indacaterol
150 mg and salmeterol exceeded the MCID, and (as in the
other three subgroups) open-label tiotropium was not
significantly more effective than placebo. The TDI and
SGRQ MCID responder rates (Table 4) also demonstrated
the greater effect of indacaterol 300 mg compared with
indacaterol 150 mg and open-label tiotropium on TDI. Raw
mean changes from baseline in SGRQ total score were
2.1 for placebo-treated patients, 3.5 for open-label
tiotropium, 4.5 for formoterol, 4.9 for salmeterol,
and 6.6 and 5.2 for indacaterol 150 mg and 300 mg
treatments, respectively.
Patients not on ICS
In this subgroup, the two doses of indacaterol were simi-
larly significantly more effective in terms of bronchodila-
tion than the twice-daily LABAs, and were the only
Table 2 Patient characteristics at baseline according to GOLD severity stage and ICS use.
GOLD stage II III
IND 150 IND 300 TIO FOR SLM PBO IND 150 IND 300 TIO FOR SLM PBO
n 448 496 236 309 189 675 298 356 179 244 143 509
Age, years 64
(9.3)
64
(8.9)
64
(9.0)
64
(8.8)
64
(9.5)
64
(9.0)
63
(8.7)
63
(8.9)
64
(8.5)
64
(8.1)
63
(8.8)
64
(8.0)
Male, % 63 67 66 71 71 68 72 79 64 81 80 79
Duration of
COPD, years
6.3
(6.83)
6.6
(6.53)
7.2
(7.72)
6.4
(6.00)
6.1
(5.48)
6.3
(5.86)
7.4
(6.10)
7.6
(7.21)
6.3
(5.43)
7.9
(5.93)
6.8
(5.98)
7.4
(6.37)
Ex-/current
smoker, %
52/48 57/43 55/45 60/40 54/46 57/43 58/42 55/45 56/44 58/42 54/46 56/44
FEV1 % pred.
a 65 (9.7) 64 (9.3) 64 (12.1) 63 (9.3) 63 (9.1) 64 (9.4) 41 (5.4) 41 (5.8) 40 (5.5) 40 (6.3) 40 (5.6) 41 (6.2)
FEV1/FVC, %
a 58 (8.0) 57 (9.0) 58 (7.7) 56 (8.9) 59 (9.0) 58 (8.8) 47 (9.0) 45 (8.6) 46 (9.4) 45 (9.3) 47 (8.5) 46 (9.1)
FEV1 pre-
SABA, L
1.56
(0.449)
1.57
(0.439)
1.53
(0.475)
1.56
(0.393)
1.60
(0.450)
1.58
(0.450)
1.02
(0.304)
1.04
(0.267)
0.96
(0.290)
1.04
(0.277)
1.03
(0.270)
1.02
(0.266)
FEV1 post-
SABA,b L
1.74
(0.458)
1.76
(0.450)
1.72
(0.470)
1.75
(0.417)
1.75
(0.448)
1.76
(0.455)
1.13
(0.273)
1.16
(0.265)
1.08
(0.262)
1.15
(0.278)
1.12
(0.269)
1.15
(0.251)
FEV1
reversibility, %
13.5
(13.95)
13.5
(12.85)
15.1
(16.12)
12.9
(13.20)
10.9
(13.32)
13.2
(14.46)
14.5
(17.57)
13.3
(15.89)
16.3
(19.49)
12.6
(12.79)
11.1
(14.62)
14.3
(17.77)
Concomitant
ICS, %
36 44 30 47 44 38 49 50 42 55 48 52
Exacerbation
history,c %
4.9 3.2 1.3 5.8 7.9 5.0 7.1 9.3 3.4 11.1 7.0 8.4
BDI score 7.1
(2.21)
7.0
(2.08)
6.8
(2.18)
7.0
(2.05)
7.1
(2.07)
6.9
(2.24)
6.0
(2.15)
6.0
(2.27)
6.2
(2.24)
5.7
(1.97)
6.1
(2.28)
5.9
(2.03)
SGRQ score 41
(18.8)
42
(17.6)
42
(18.3)
41
(16.7)
40
(17.7)
41
(17.2)
49
(18.0)
49
(17.6)
48
(17.5)
49
(17.1)
48
(18.6)
49
(17.2)
ICS status No ICS ICS
n 438 455 270 276 181 661 308 398 145 280 152 524
Age, years 63
(9.1)
63
(9.3)
63
(8.9)
64
(8.7)
64
(9.1)
63
(8.9)
64
(9.0)
64
(8.5)
65
(8.5)
65
(8.4)
63
(9.3)
64 (8.1)
Male, % 69 73 67 75 76 74 63 70 60 75 74 72
Duration of
COPD, years
6.9
(5.90)
6.3
(6.60)
6.2
(6.40)
6.6
(5.98)
5.6
(4.84)
6.2
(5.93)
8.0
(7.24)
7.9
(7.09)
8.1
(7.44)
7.5
(6.00)
7.3
(6.46)
7.5
(6.26)
Ex-/current
smoker, %
49/51 51/49 51/49 53/47 51/49 54/46 63/37 63/37 63/37 65/35 57/43 59/41
FEV1 % pred. 57
(14.7)
56
(14.7)
56
(15.8)
55
(14.4)
54
(14.4)
56
(14.4)
53
(13.3)
53
(13.4)
51
(14.7)
52
(13.5)
52
(12.7)
51
(13.6)
FEV1/FVC, % 54
(10.0)
52
(10.5)
54
(9.6)
53
(10.3)
53
(10.3)
54
(10.6)
52
(9.8)
51
(10.3)
51
(10.8)
50
(10.3)
52
(9.3)
51
(10.4)
FEV1 pre-
SABA,b L
1.41
(0.502)
1.40
(0.491)
1.36
(0.502)
1.40
(0.448)
1.34
(0.493)
1.41
(0.495)
1.24
(0.423)
1.29
(0.414)
1.14
(0.448)
1.27
(0.411)
1.36
(0.458)
1.25
(0.430)
FEV1 post-
SABA,b L
1.57
(0.515)
1.56
(0.510)
1.52
(0.519)
1.54
(0.487)
1.48
(0.500)
1.57
(0.508)
1.40
(0.447)
1.45
(0.450)
1.32
(0.453)
1.44
(0.441)
1.47
(0.483)
1.41
(0.451)
FEV1
reversibility, %
13.1
(14.77)
13.4
(14.50)
14.1
(17.52)
11.0
(12.99)
12.3
(13.68)
13.3
(16.72)
15.0
(16.42)
13.4
(13.84)
18.5
(17.57)
14.4
(12.80)
9.3
(13.94)
14.1
(14.97)
GOLD II/III 65/35 61/39 61/39 59/40 58/41 63/37 53/47 55/45 48/52 52/48 55/45 49/51
Exacerbation
history,c %
4.1 4.0 0.7 6.9 9.9 5.6 8.1 7.8 4.8 9.3 4.6 7.6
BDI score 6.9
(2.19)
6.6
(2.13)
6.7
(2.22)
6.6
(2.06)
6.7
(2.31)
6.6
(2.29)
6.3
(2.30)
6.5
(2.31)
6.4
(2.24)
6.3
(2.14)
6.7
(2.11)
6.3
(2.11)
SGRQ score 43
(19.2)
45
(18.1)
45
(18.5)
44
(17.7)
42
(19.8)
44
(17.8)
47
(18.4)
45
(17.6)
43
(17.4)
45
(16.9)
44
(16.8)
45
(17.4)
Data are means (SD) unless otherwise stated. IND Z indacaterol; TIO Z open-label tiotropium; FOR Z formoterol; SLM Z salmeterol;
PBO Z placebo; ICS Z inhaled corticosteroid; SABA Z short-acting b2-agonist; BDI Z baseline dyspnoea index; SGRQ Z St George’s
Respiratory Questionnaire.
a Assessed within 30 min after inhaling 400 mg salbutamol.
b 30 min after inhaling salbutamol 400 mg.
c Percentage of subjects with at least one exacerbation in previous 12 months.
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Figure 1 Effect of treatments (activeeplacebo differences) on trough FEV1, TDI total score and SGRQ total score after 26 weeks
of treatment in the four subgroups of patients. The shaded area bounds the MCID for trough FEV1 (120 mL), TDI total score (þ1) and
SGRQ total score (4.0); effects outside the shaded area are >MCID. All activeeplacebo differences statistically significant
(p < 0.05) apart from effect of tiotropium on SGRQ in all subgroups. Other significant (p < 0.05) differences: zvs. formoterol;
xvs. salmeterol; yvs. tiotropium; {vs. indacaterol 150 mg; and #vs. indacaterol 300 mg. IND Z indacaterol; TIO Z open-label
tiotropium; FOR Z formoterol; SLM Z salmeterol; PBO Z placebo.
Table 3 Patients (n, %) completing 6 months’ treatment in the subgroups.
GOLD stage II III
IND 150 IND 300 TIO FOR SLM PBO IND 150 IND 300 TIO FOR SLM PBO
n 448 496 236 309 189 675 298 356 179 244 143 509
Completed 354 (79) 398 (80) 184 (78) 252 (82) 163 (86) 501 (74) 242 (81) 269 (76) 147 (82) 181 (74) 120 (84) 333 (65)
ICS status No ICS ICS
IND 150 IND 300 TIO FOR SLM PBO IND 150 IND 300 TIO FOR SLM PBO
n 438 455 270 276 181 661 308 398 145 280 152 524
Completed 335 (77) 354 (78) 209 (77) 221 (80) 151 (83) 474 (72) 261 (85) 314 (79) 122 (84) 214 (76) 133 (88) 361 (69)
INDZ indacaterol; TIOZ open-label tiotropium; FORZ formoterol; SLMZ salmeterol; PBOZ placebo; ICSZ inhaled corticosteroid.
Bronchodilator efficacy by COPD severity and ICS use 227
Table 4 Percentages of patients achieving the MCID and associated odds ratios (95% CI) vs. placebo for TDI total score (1
point) and for SGRQ total score (4 units). Odds ratios for all significant differences between active treatments are included.
*p < 0.05; **p < 0.01; ***p < 0.001.
GOLD II GOLD III No ICS ICS
TDI
PBO % 49.3 39.5 49.4 40.2
IND 150 % 63.8 55.7 66.0 53.1
OR 1.99 (1.45, 2.74)*** 1.79 (1.23, 2.61)** 2.17 (1.57, 3.00)***
1.54 (1.03, 2.30)*
vs. TIO
1.64 (1.14, 2.36)**
IND 300 % 66.8 64.6 68.1 63.4
OR 2.44 (1.79, 3.31)***
1.53 (1.01, 2.31)*
vs. TIO
3.11 (2.13, 4.54)***
2.22 (1.38, 3.56)***
vs. TIO1.73 (1.14,
2.65)* vs. IND 150
2.59 (1.86, 3.59)***
1.83 (1.22, 2.74)**
vs. TIO
1.76 (1.07, 2.92)*
vs. SLM
2.84 (2.01, 4.03)***
1.74 (1.07, 2.83)*
vs. TIO
TIO % 64.6 49.3 58.3 57.0
OR 1.59 (1.07, 2.37)* 1.40 (0.89, 2.20) 1.41 (0.96, 2.08) 1.64 (1.03, 2.60)*
FOR % 57.3 49.6 60.8 48.2
OR 1.91 (1.29, 2.84)** 2.18 (1.35, 3.52)** 2.25 (1.44, 3.51)*** 1.88 (1.22, 2.88)**
SLM 56.9 50.8 54.1 54.2
1.72 (1.12, 2.66)* 1.95 (1.18, 3.22)** 1.47 (0.94, 2.30) 2.19 (1.36, 3.54)**
SGRQ
PBO % 42.0 40.9 42.2 40.6
IND 150 % 57.0 53.6 61.6 47.7
OR 2.14 (1.59, 2.88)*** 1.69 (1.18, 2.41)** 2.56 (1.89, 3.48)***
1.69 (1.11, 2.58)*
vs. FOR;
1.93 (1.32, 2.82)***
vs. xTIO
1.37 (0.97, 1.94)
IND 300 % 55.5 51.5 57.1 50.5
OR 1.78 (1.34, 2.37)*** 1.42 (1.00, 2.02)* 1.85 (1.37, 2.51)*** 1.43 (1.03, 1.98)*
TIO % 51.8 42.7 48.8 46.1
OR 1.46 (1.01, 2.10)* 1.08 (0.71, 1.66) 1.33 (0.93, 1.90) 1.28 (0.82, 1.98)
FOR % 52.2 49.4 50.3 51.5
OR 1.63 (1.15, 2.30)** 1.42 (0.94, 2.16) 1.51 (1.04, 2.21)* 1.55 (1.06, 2.27)*
SLM % 50.3 47.5 52.0 45.5
OR 1.98 (1.31, 2.99)** 1.66 (1.03, 2.66)* 2.10 (1.37, 3.21)*** 1.50 (0.95, 2.36)
OR Z odds ratio; IND Z indacaterol; TIO Z open-label tiotropium; FOR Z formoterol; SLM Z salmeterol; PBO Z placebo.
228 M. Decramer et al.treatments to exceed the MCID for TDI (Fig. 1). Odds ratios
for achieving the MCID in TDI were significantly greater with
indacaterol compared with open-label tiotropium (both
doses) and salmeterol (indacaterol 300 mg) (Table 4).
Indacaterol 150 mg improved SGRQ by more than the MCID
and was significantly more effective than formoterol, open-
label tiotropium and indacaterol 300 mg (Fig. 1). Odds ratios
for achieving the SGRQ MCID were significantly higher with
indacaterol 150 mg than formoterol and open-label tio-
tropium, while the effect of salmeterol did not differ
significantly from placebo (Table 4).
Patients on ICS
Indacaterol had a greater effect on trough FEV1 than the
twice-daily LABAs (both doses) and open-label tiotropium
(150 mg dose only); the 300 mg dose had a significantly
greater effect than the 150 mg dose (Fig. 1). The 300 mgdose was significantly more effective than formoterol and
the lower dose of indacaterol in its effect on TDI (Fig. 1)
and had a significantly higher odds ratio for achieving the
MCID in TDI than open-label tiotropium (Table 4), and
narrowly failed to achieve the MCID for SGRQ (3.6 units
vs. placebo).
The effects of all the b2-agonists on SGRQ were clus-
tered closely around the MCID, but only salmeterol excee-
ded the MCID (4.1 vs. placebo). However, the odds ratio
for achieving the MCID in SGRQ with salmeterol did not
differ significantly from placebo (Table 4).
Safety
Table 5 presents the overall incidence of adverse events
and those most commonly occurring in each of the
subgroups. Within each of the subgroups, the overall inci-
dence of adverse events was numerically highest with
Table 5 Adverse events overall and most commonly
occurring (>5% of any treatment group) (% of patients)
according to COPD severity and ICS use.
IND 150 IND 300 FOR SLM TIO PBO
GOLD II
Any adverse event 58.9 61.3 57.9 45.0 67.0 55.9
COPD worsening 14.5 13.9 15.2 14.8 13.1 17.8
Nasopharyngitis 7.8 10.1 8.7 10.1 10.2 8.2
Upper RTI 6.5 5.0 2.6 0.0 5.5 3.3
Cough 5.6 7.3 4.2 2.7 5.9 4.3
GOLD III
Any adverse event 60.7 60.1 53.3 46.9 67.6 51.3
COPD worsening 22.5 24.7 24.2 16.1 27.9 25.7
Nasopharyngitis 7.4 9.0 7.4 7.0 6.7 6.9
Cough 5.0 5.6 2.9 2.8 6.7 4.7
Upper RTI 4.4 5.6 2.9 0.7 10.1 4.7
No ICS
Any adverse event 56.2 58.0 52.2 45.3 64.4 54.5
COPD worsening 11.4 13.4 16.3 12.2 14.4 18.9
Nasopharyngitis 6.2 9.2 9.1 8.3 8.2 6.8
Cough 6.6 7.0 2.9 2.8 5.2 5.0
Upper RTI 5.5 4.8 2.5 0.0 7.0 4.1
Lower RTI 0.7 2.4 1.1 3.3 1.5 2.9
ICS
Any adverse event 64.6 64.1 59.3 46.1 72.4 53.2
COPD worsening 26.6 24.4 21.8 19.1 29.0 24.2
Nasopharyngitis 9.7 10.1 7.1 9.2 9.7 8.6
Lower RTI 6.5 4.0 2.5 4.6 6.9 3.1
Upper RTI 5.8 5.8 3.2 0.7 8.3 3.6
Cough 3.6 6.0 4.3 2.6 8.3 3.8
IND Z indacaterol; TIO Z open-label tiotropium;
FOR Z formoterol; SLM Z salmeterol; PBO Z placebo;
ICSZ inhaled corticosteroids; RTIZ respiratory tract infection.
See Table 2 for patient numbers.
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compared with placebo and with the other active treat-
ments, where the incidence was similar. In all subgroups
and treatment groups, the commonest adverse events were
those affecting the respiratory tract. Comparing the
subgroups, the incidence of COPD worsening was higher in
the GOLD III subgroup than in the GOLD II subgroup, and
higher in the patients receiving ICS than in those who were
not. The incidence of lower respiratory tract infection (RTI)
was numerically higher in those receiving ICS than in those
who were not (4.2% [76/1807] vs. 2.0% [46/2281]).Discussion
The present analysis enables us to evaluate the relative
efficacy of inhaled long-acting bronchodilators in terms of
both bronchodilator effect and the clinical outcomes of
dyspnoea and health status in different populations of
patients with COPD, over a period of time that is long
enough to be relevant to clinical practice. Comparing the
two disease severity subgroups, treatment effects were
generally larger in the GOLD II patients than in the GOLD III
patients. Similar findings were observed in the subgroup
analyses from the large, long-term UPLIFT12 and TORCH13studies, which demonstrated the benefits of treating
patients with GOLD stage II disease. This has important
implications for early treatment of COPD, especially as
recent studies have shown that patients with moderate
disease may experience a more rapid decline in lung
function than those with more severe disease.14e16
Considering the effects of treatment on the outcomes
assessed in the present analysis, we would judge indaca-
terol 150 mg to be the most effective treatment for those
patients with GOLD stage II disease, not only as a broncho-
dilator but also in terms of improvement in dyspnoea and
health status, with all improvements exceeding the
threshold for a clinically relevant effect. Compared with
open-label tiotropium, a widely used bronchodilator in
COPD, indacaterol 150 mg was significantly more effective
at improving health status. A similar pattern of treatment
effect was observed in patients in the no-ICS subgroup,
which overlapped to a large extent with the GOLD II
subgroup. There was little difference between the effects
of the two doses of indacaterol in patients in the GOLD II
and no-ICS subgroups. However, it was interesting to
observe that in the GOLD III and ICS subgroups (again, with
a large degree of overlap) it was the 300 mg dose of inda-
caterol that appeared to have the best overall profile of
efficacy, and was significantly more effective than the
150 mg dose in its effect on dyspnoea. These improvements
in dyspnoea are particularly important, since breathless-
ness is the most disabling symptom for COPD patients.17,18
In a recently published survey of 1084 COPD patients
receiving monotherapy with a long-acting bronchodilator
(tiotropium was used by 76%, formoterol by 14% and sal-
meterol by 9%), many patients had poor health status and
experienced significant symptoms, and those with more
severe disease had worse dyspnoea.19 It appears that there
is a therapeutic need for a more effective long-acting
bronchodilator, and the 300 mg dose of indacaterol may
be a particularly useful option for patients with severe
dyspnoea. Renard and colleagues20 modelled the relation-
ship between indacaterol dose and bronchodilator response
(steady-state trough FEV1) using data from placebo-
controlled studies of at least 14 days in duration in
patients with COPD, and found a clinically relevant bron-
chodilator effect (difference of 120 mL vs. placebo) with
doses of 75 mg once daily and higher. When the broncho-
dilator dose-response was modelled according to disease
severity, patients with moderate COPD were predicted to
have a steeper dose-response with a larger maximum
response, whereas patients with severe COPD had a shal-
lower dose response with a lower maximum response. Thus,
compared with those with moderate COPD, the dose-
response plateau is reached at higher doses in patients
with severe COPD such that the higher doses would have
a relatively greater impact, which was reflected in the
greater separation of effect between the 150 and 300 mg
doses in the severe subgroup in the present analysis.20 An
indacaterol dose of 75 mg once daily is the only approved
dose for use in the USA and Canada, but did not form part of
the studies from which the present population was drawn.
Those two countries approved the lower of two indacaterol
doses submitted for evaluation (75 and 150 mg) on the basis
that indacaterol 75 mg was judged to be the minimally
effective dose. However, both doses were considered to
230 M. Decramer et al.have an adequate safety profile.21 A dose of 600 mg (not
approved for use in any country) was evaluated over 1 year
and was reported to be well tolerated.3 The GOLD stages in
the present analysis reflect the level of airflow limitation,
which at the time of enrolment into the studies was how
GOLD classified overall COPD severity, with treatment
recommendations for each severity stage. GOLD now uses
this staging to classify airflow limitation and makes treat-
ment recommendations according to symptoms (assessed
by the modified Medical Research Council or COPD Assess-
ment Test instruments) and patient risk, which depends on
a combination of severity of airflow limitation (GOLD IeIV)
and exacerbation history.1 Following GOLD guidelines, high-
risk patients as defined by GOLD IIIeIV or repeated exac-
erbations1,22 would be treated with ICS. Interestingly, in
this pooled analysis only 9% of patients classified as GOLD III
had a COPD exacerbation in the 12 months prior to entering
the studies, yet 50% of them were on concomitant ICS.
However, patients in the GOLD III and ICS subgroups had
a notably higher incidence of COPD worsening as an adverse
event, a definition that would have encompassed a range
from worsening symptoms to exacerbations of COPD, which
may provide a reason for the ICS use. Baseline data also
showed that 35% of patients with GOLD II COPD were
treated with ICS and, although our data are insufficient to
know if some of the GOLD II patients were receiving ICS for
repeated exacerbations, only 5% had reported an exacer-
bation in the previous year. Patients with a history of
asthma were not enrolled in the indacaterol studies, so it is
very unlikely that the ICS were being given for mixed-
disease asthma and COPD. Baseline reversibility was
comparable between ICS and non-ICS groups and should
therefore not have been an underlying factor in ICS use.
A high level of ICS in patients with moderate COPD has
been reported elsewhere.23e28 The potential over-use of
ICS may be of concern, since the higher risk:benefit ratio
associated with the use of ICS in COPD than in asthma
suggests that these agents should be administered within
GOLD guideline recommendations.29,30 Arguably the most
concerning side-effect of ICS in COPD is the increased risk
of pneumonia,31e35 which may be reflected in the increased
incidence of lower RTI in the ICS-using patients in the
present analysis. Although the incidence of pneumonia was
similar between no-ICS and ICS subgroups, cases of pneu-
monia may have been included in the category of LRTI.
Radiographic confirmation of pneumonia or LRTI was not
routinely obtained in the studies contributing to the
present analysis.
Finally, it is important to note that there were a number
of limitations in this post-hoc analysis. Analysis of
subgroups such as these results in small patient numbers,
particularly in the active comparator groups (data for open-
label tiotropium, formoterol and salmeterol came from
a single study each), where results may need to be inter-
preted with caution owing to a relative lack of power to
detect differences. The highest patient numbers were in
the indacaterol and placebo treatment groups, and these
provide the most robust comparisons. Furthermore, the
open-label administration of tiotropium4 also raises the
possibility that results were biased in one direction or the
other, particularly for the more subjective outcome
measures. In addition, none of the variables in this analysiswas a primary outcome in the three source studies,
although one of those studies was powered to detect
indacateroleplacebo differences in SGRQ.5 Another, more
general consideration in drug trials in COPD is that the
difference between active and placebo treatments for
SGRQ is usually influenced by improvement in SGRQ scores
in the placebo group, due to two factors. One is the ‘trial’
effect on medication intake in the placebo group, which (as
shown here by the change from baseline data) is likely to be
larger in patients with less severe COPD. The second is the
higher drop-out rate from placebo compared with active
treatments, which, as we observed, is likely to be more
prominent in patients with more severe COPD compared
with those with milder disease.
Conclusion
Indacaterol maintained its efficacy with a good profile of
tolerability regardless of COPD severity or concurrent ICS
use. Indacaterol would be an appropriate initial mainte-
nance therapy for patients with COPD. In patients with
more severe disease (GOLD stages III), the 300 mg dose of
indacaterol may provide additional control of dyspnoea.
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